Infliximab for the treatment of refractory immune-related hepatitis secondary to checkpoint inhibitors: A case report

JHEP Rep. 2019 Apr 11;1(1):66-69. doi: 10.1016/j.jhepr.2019.02.001. eCollection 2019 May.

Margaret Corrigan^{1

2}, Geoffrey Haydon², Fiona Thompson², Neil Rajoriya², Claire L Peplow², Stefan G Hubscher³, Neil Steven⁴, Gideon M Hirschfield^{1

2

4

5}, Matthew J Armstrong^{1

2

4}

¹ National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre, Birmingham, UK.
² The Liver Unit, Queen Elizabeth University Hospitals Birmingham, Birmingham, UK.
³ Department of Cellular Pathology, University Hospitals Birmingham, Birmingham, UK.
⁴ Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
⁵ Toronto Centre for Liver Disease, University Health Network, University of Toronto, Toronto, Canada.

No abstract available

Keywords: Hepatitis; Immunotherapy; Infliximab; checkpoint.